PRIA Logo™
Take the PRIA Score
Title 42 — The Public Health and WelfareRelease 119-73

§285o–2 Drug Abuse Research Centers

Title 42 › Chapter CHAPTER 6A— - PUBLIC HEALTH SERVICE › Subchapter SUBCHAPTER III— - NATIONAL RESEARCH INSTITUTES › Part Part C— - Specific Provisions Respecting National Research Institutes › Subpart subpart 15— - national institute on drug abuse › § 285o–2

Last updated Apr 6, 2026|Official source

Summary

The Director can name National Drug Abuse Research Centers to do long-term, team-based research on drug abuse and related medical, behavioral, and social issues. Any group must apply and get the Secretary’s approval. The application must show the group can run interdisciplinary research, has labs and data facilities, can train people to prevent and treat drug abuse, can train predoctoral and postdoctoral researchers, can teach students in medicine, nursing, social work and related fields, and can provide continuing education. The application must also include a detailed five-year research plan. The Director must give yearly grants to approved Centers under rules the Secretary sets, but grant money cannot buy land or be used to buy, build, preserve, or repair buildings. The Director can also fund or make agreements to expand research and clinical trials with centers in the National Drug Abuse Treatment Clinical Trials Network. Funded work may cover studies of effects on the body and brain; how addiction varies by person; links between drug abuse and mental health; prevention and treatment methods (including medicines); risk factors; effects on pregnant women and fetuses; and cultural, social, behavioral, neurological, and psychological reasons people do or do not abuse drugs. The Director must quickly share research results with federal, state, and local groups fighting drug abuse.

Full Legal Text

Title 42, §285o–2

The Public Health and Welfare — Source: USLM XML via OLRC

(a)The Director of the Institute may designate National Drug Abuse Research Centers for the purpose of interdisciplinary research relating to drug abuse and other biomedical, behavioral, and social issues related to drug abuse. No entity may be designated as a Center unless an application therefore has been submitted to, and approved by, the Secretary. Such an application shall be submitted in such manner and contain such information as the Secretary may reasonably require. The Secretary may not approve such an application unless—
(1)the application contains or is supported by reasonable assurances that—
(A)the applicant has the experience, or capability, to conduct, through biomedical, behavioral, social, and related disciplines, long-term research on drug abuse and to provide coordination of such research among such disciplines;
(B)the applicant has available to it sufficient facilities (including laboratory, reference, and data analysis facilities) to carry out the research plan contained in the application;
(C)the applicant has facilities and personnel to provide training in the prevention and treatment of drug abuse;
(D)the applicant has the capacity to train predoctoral and postdoctoral students for careers in research on drug abuse;
(E)the applicant has the capacity to conduct courses on drug abuse problems and research on drug abuse for undergraduate and graduate students, and medical and osteopathic, nursing, social work, and other specialized graduate students; and
(F)the applicant has the capacity to conduct programs of continuing education in such medical, legal, and social service fields as the Secretary may require.11 So in original. The period probably should be “; and”.
(2)the application contains a detailed five-year plan for research relating to drug abuse.
(b)The Director of the Institute shall, under such conditions as the Secretary may reasonably require, make annual grants to Centers which have been designated under this section. No funds provided under a grant under this subsection may be used for the purchase of any land or the purchase, construction, preservation, or repair of any building. For the purposes of the preceding sentence, the term “construction” has the meaning given that term by section 292a(1) 22 See References in Text note below. of this title.
(c)(1)The Director of the Institute may make grants or enter into cooperative agreements to expand the current and ongoing interdisciplinary research and clinical trials with treatment centers of the National Drug Abuse Treatment Clinical Trials Network relating to drug abuse and addiction, including related biomedical, behavioral, and social issues.
(2)Amounts made available under a grant or cooperative agreement under paragraph (1) for drug abuse and addiction may be used for research and clinical trials relating to—
(A)the effects of drug abuse on the human body, including the brain;
(B)the addictive nature of drugs and how such effects differ with respect to different individuals;
(C)the connection between drug abuse and mental health;
(D)the identification and evaluation of the most effective methods of prevention of drug abuse and addiction;
(E)the identification and development of the most effective methods of treatment of drug addiction, including pharmacological treatments;
(F)risk factors for drug abuse;
(G)effects of drug abuse and addiction on pregnant women and their fetuses; and
(H)cultural, social, behavioral, neurological, and psychological reasons that individuals abuse drugs, or refrain from abusing drugs.
(3)The Director shall promptly disseminate research results under this subsection to Federal, State, and local entities involved in combating drug abuse and addiction.

Legislative History

Notes & Related Subsidiaries

Editorial Notes

References in Text

section 292a of this title, referred to in subsec. (b), was in the original a reference to section 701 of act
July 1, 1944. section 701 of that Act was omitted in the general revision of subchapter V of this chapter by Pub. L. 102–408, title I, § 102, Oct. 13, 1992, 106 Stat. 1994. Pub. L. 102–408 enacted a new section 701 of act
July 1, 1944, relating to statement of purpose, and a new section 702, relating to scope and duration of loan insurance program, which are classified to section 292 and 292a, respectively, of this title. For provisions relating to definitions, see section 292o and 295p of this title.

Amendments

2007—Subsec. (c)(4). Pub. L. 109–482 struck out par. (4) which authorized appropriations and provided they were supplemental to other funding of research on drug abuse. 2002—Subsec. (c). Pub. L. 107–273 amended heading and text of subsec. (c) generally, substituting provisions relating to grants or cooperative agreements for research and clinical trials relating to drug abuse and addiction for similar provisions relating to grants or cooperative agreements for research and clinical trials relating to methamphetamine abuse and addiction. 2000—Subsec. (c). Pub. L. 106–310 added subsec. (c). 1992—Subsec. (b). Pub. L. 102–352 substituted “292a(1)” for “292a(2)”.

Statutory Notes and Related Subsidiaries

Effective Date

of 2007 AmendmentAmendment by Pub. L. 109–482 applicable only with respect to amounts appropriated for fiscal year 2007 or subsequent fiscal years, see section 109 of Pub. L. 109–482, set out as a note under section 281 of this title.

Effective Date

of 1992 AmendmentAmendment by Pub. L. 102–352 effective immediately upon effectuation of amendment made by Pub. L. 102–321, see section 3(1) of Pub. L. 102–352, set out as a note under section 285n of this title.

Effective Date

Section effective Oct. 1, 1992, with provision for programs providing financial assistance, see section 801(c), (d) of Pub. L. 102–321, set out as an

Effective Date

of 1992 Amendment note under section 236 of this title.

Reference

Citations & Metadata

Citation

42 U.S.C. § 285o–2

Title 42 — The Public Health and Welfare

Last Updated

Apr 6, 2026

Release point: 119-73